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Abstract
This study was aimed at establishing the genetic heterogeneity of influenza virus haemagglutinin (HA) gene quasi-species and the
polymorphisms at codon 222, by application of ultra-deep pyrosequencing (UDPS) to respiratory samples from patients hospitalized for
influenza A(H1N1)pdm09 infection, presenting with severe or moderate–mild disease. HA diversity was significantly higher in samples
collected from patients with severe manifestations than in those from patients with moderate–mild manifestations (p 0.02). D222
polymorphism was detected in 40.7% of patients by UDPS, and in only 7.1% by Sanger sequencing. D222E, D222G, D222N and D222A
were observed in 37.0%, 11.1%, 7.4% and 3.7% of patients, respectively; 10.7% of samples harboured more than two variants. The
relative frequency of each single variant showed a wide range of intrapatient variation. D222G/N/A were detected, as either minor or
predominant variants, only in severe cases, whereas D222E was equally represented in severe and moderate–mild infections. Other
amino acid variants were observed at different positions within the analysed HA fragment. Consistent with higher heterogeneity,
non-D222 variants were more frequently detected in severe cases than in moderate–mild cases. In addition, seven non-D222 mutations
carried by minority variants, not previously described, were observed.
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Background
The 2009 pandemic sustained by the influenza A(H1N1)pdm09
virus has been relatively mild, with moderate and self-limiting
upper respiratory tract illness and no sign of pulmonary involve-
ment in most cases. Nevertheless, in sporadic cases, influ-
enza A(H1N1)pdm09 infections caused severe pneumonia and
acute respiratory distress syndrome (ARDS), with patients
requiring admission to intensive-care units and maximal life sup-
port measures [1].
Increased virulence of strains carrying the D222G/N sub-
stitutions in the receptor-binding glycoprotein of the virus
(haemagglutinin (HA)) has been suggested, as these substitu-
tions have been described in critically ill patients [2–9],
whereas this issue is more controversial for the D222E sub-
stitution [2,10].
Influenza virus may be present in the infected host as a
mixture of variants, referred to as quasi-species [11]. Next-
generation sequencing (NGS) has emerged as an important
tool with which to investigate minority variants in viral quasi-
species for a number of viruses, including HIV, hepatitis C
virus, and hepatitis B virus [12–15]. For influenza virus, the
concomitant presence of different HA variants in clinical
samples from patients infected with influenza A(H1N1)pdm09
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has been detected with the metagenomic approach, based on
different NGS platforms [16,17]. In addition, ultra-deep
pyrosequencing (UDPS), based on the amplicon approach,
has been used to evaluate the intrapatient heterogeneity of
the HA gene, to detect the emergence of oseltamivir resis-
tance [18].
In this study, UDPS was applied to respiratory samples from
patients hospitalized for influenza A(H1N1)pdm09 infection,
with the aim of establishing possible correlations between viral
heterogeneity and the presence of variants (mainly focusing on
position 222) with clinical presentations of the disease.
Materials and Methods
Patients
Thirty-two patients, previously screened by standard Sanger
sequencing (Ss) for the presence of amino acid polymor-
phisms at codon 222 of the HA gene of influ-
enza A(H1N1)pdm09, were considered, giving a total of 36
samples (28 nasal swabs (NSs) and eight bronchoalveolar la-
vages (BALs)). All specimens were collected before antiviral
treatment initiation.
Detailed descriptions of patient selection criteria and of
ethical aspects are included in Data S1. Briefly, patients were
stratified according to the criteria proposed by Zarychanski
et al. [19], as follows: (i) ten (31.3%) patients with severe
influenza-like illness (ILI); (ii) 12 (37.5%) patients with moder-
ate ILI; and (iii) ten (31.3%) patients with mild ILI.
According to clinical conditions, the patients were
assigned to two groups: severe ILI (group A) and mild–mod-
erate ILI (group B).
Sequencing
Nucleic acids from NS or BAL purification, reverse transcrip-
tion reaction, viral load determination and Ss were per-
formed as previously described [8]. For each sample, the
amount of cDNA subjected to UDPS analysis corresponded
almost exactly to the copies present in 1 mL of the starting
material (Table 1).
UDPS was carried out with the 454 Life Sciences platform
(GS-FLX; Roche Applied Science, Monza, Italy) as previously
described [12], using titanium chemistry.
UDPS error rate estimation
To measure the accuracy of the UDPS, a plasmid clone
containing the region of interest was sequenced in parallel
by UDPS and by Ss. The plasmid clone was obtained from
a patient sample by inserting the PCR amplicon into a
pCR2.1-TOPO vector (InvitrogenTM; Life Technologies,
Monza, Italy). Differences between the two methods were
considered to be GS-FLX sequencing errors.
GS Amplicon Variant Analyzer software (v.2.5.3; Roche
Applied Science) was used to correct GS-FLX sequences and
to identify the substitutions. Namely, the sequences obtained
by UDPS were aligned with the Ss clone sequence, and for
each position the error rate was estimated, distinguishing
deletions, substitutions, and insertions. The calculated error
rates were 0.032%, 0.035% and 0.069% for the different sub-
stitution types.
On the basis of previous experience [13], we considered
as true variability all changes whose frequency was at least
0.21%, i.e. three times the insertion error rate, which was
the highest frequency of procedural/experimental errors. In
our experimental conditions, the number of cDNA templates
undergoing UDPS and the resulting coverage (Table 1) were
sufficiently high to rule out a possible influence on this sensi-
tivity threshold, according to previous estimates [20].
The amplification conditions for UDPS and the bioinfor-
matics analysis are described in Data S1.
Statistical evaluation
For most variables, descriptive statistics, such as median with
interquartile range (IQR), and proportion (%), were calcu-
lated. The Mann–Whitney U-test and v2-tests (or Fisher’s
exact test when applicable) were used for univariate analysis,
as appropriate. A two-tailed p-value of <0.05 was considered
to be significant.
For calculation of the frequency of the HA substitutions,
each substitution was individually counted.
Results
Overall, UDPS was applied to 27 of 32 (84.4%) patients, for
whom sufficient amounts of viral RNA had been obtained to
perform NGS in addition to Ss. Of these patients, eight had
severe ILI (group A) and 19 had moderate–mild ILI
(group B). For one patient from group B, paired samples
(BAL and NS) were analysed. The median ages were
38.0 years (IQR 28.8–47.0 years) for group A and 43.0 years
(IQR 25.0–57.0 years) for group B (non-significant differ-
ence). The median duration of illness at the time of sampling,
calculated as number of days from the start of symptoms to
sample collection, was significantly higher for group A than
for group B (median of 5 days (IQR 4.5–6.5 days) vs. 2 days
(IQR 1–3 days); p 0.03). At presentation, all patients of
group A had ARDS, while patients of group B had fever
plus at least one of the following symptoms: pneumonia,
cough, dyspnea, rhinitis, myalgia and pharyngodynia. The
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demographic and clinical characteristics of the 27 patients
are shown in Table S1.
In Table 1, viral load values, HA quasi-species diversity,
and polymorphisms, detected at position 222 in the 28 sam-
ples successfully analysed by UDPS, are reported, along with
the results obtained with Ss. Median viral load values in
group A were significantly lower than in group B (5.88
log10 copies/mL, IQR 5.45–6.74 vs. 7.31 log10 copies/mL,
IQR 6.33–8.22; p 0.01). A total of 370 462 sequences from
all samples were obtained by UDPS. The intrasample diver-
sity in group A was significantly higher than that in group B
(median (IQR): 1.66 (0.95–15.29) · 10)4 vs. 0.69 (0.43–
1.18) · 10)4 substitutions per site, p 0.02); diversity was not
significantly correlated with the duration of illness (r2 = 0.17,
p 0.073). The median diversity in NS samples was not signifi-
cantly different from that in BAL samples (median (IQR):
0.85 (0.29–1.45) · 10)4 vs. 2.13 (0.68–32.14) · 10)4 substi-
tutions per site; p 0.20).
Concerning position 222, a single variant, i.e. the refer-
ence D222, was detected by both UDPS and Ss in four
patients from group A and in 13 patients from group B
(including the patient with double sample type, i.e. patient
no. 9). The concomitant presence of multiple variants was
detected by UDPS in 11 of 27 patients (40.7%), four from
group A and seven from group B. Eight patients harboured
two variants (E/D), two patients harboured three variants
(E/D/G and D/N/G), and one patient harboured five variants
(D/N/G/E/A). There was high intrapatient variability in the
frequency of each position 222 variant, which ranged
between 0.27% (minority population) and 100% (pure popu-
lation). In addition, the D222 reference was always detected
in samples with variants, accounting for 0.37–65.79% of the
overall quasi-species. D222E was the most frequent variant
in both severe and moderate–mild patients, whereas D222G,
D222N and D222A were present (eventually as minority
quasi-species) only in samples from patients with severe
TABLE 1. Quasi-species haemagglutinin diversity and position 222 polymorphisms in 28 clinical samples from patients with








Position 222 variant detected
Coveragec DiversitydSanger UDPSb
Frequency of variant
estimated by UDPS (%)
A 1 BAL 6.01 E E/D/G 98.93/0.80/0.27 7349 3.27
2 BAL 5.75 D/N D/N/G/E/A 34.03/43.82/19.06/2.28/0.65 4466 41.76
3 BAL 7.11 D D 100 16 100 0.99
4 NS 5.44 D D 100 11 340 1.38
5 NS 4.37 D/G D/G/N 65.79/33.18/1.00 14 231 19.29
6 NS 5.47 E E/D 99.63/0.37 7310 0.63
7 NS 6.84 D D 100 16 205 1.93
8 NS 6.44 D D 100 8615 0.93
Median (IQR) 5.88 (5.45–6.74) 1.66
(0.95–15.29)
B 9 NS 4.86 D D 100 21 257 1.06
BAL 7.66 D D 100 9651 0.57
10 NS 8.24 D D 100 15 446 0.69
11 NS 6.67 E E/D 99.57/0.43 14 176 0.86
12 NS 5.84 D D 100 13 118 1.22
13 NS 6.74 D D 100 15 881 0.29
14 NS 7.07 D D 100 12 416 0.52
15 NS 6.86 E E/D 99.60/0.40 5545 0.50
16 NS 8.16 D D 100 16 425 0.92
17 NS 6.21 D D 100 13 762 1.47
18 NS 6.00 D D 100 9020 4.06
19 NS 5.62 E E/D 99.58/0.42 16 045 2.62
20 NS 8.17 E E/D 99.37/0.63 15 806 0.41
21 NS 8.32 D D 100 19 536 0.44
22 NS 8.61 D D 100 13 802 0.84
23 NS 7.58 E E/D 99.39/0.61 15 791 0.41
24 NS 7.36 E E/D 99.34/0.66 18 026 0.29
25 NS 7.26 D D 100 11 170 0.42
26 NS 8.92 E E/D 99.34/0.66 22 042 18.10
27 NS 8.92 D D 100 5931 0.69
Median (IQR) 7.31 (6.33–8.22) 0.69
(0.43–1.18)
p (A vs. B)e 0.01 0.02
BAL, bronchoalveolar lavage; IQR, interquartile range; NS, nasal swab; UDPS, ultra-deep pyrosequencing.
aViral load also represents the number of cDNA copies subjected to UDPS, as there was 1 mL of starting material, and all of the extracted RNA was reverse transcribed
and sequenced.
bThe order of the variants is in accordance with their relative frequency in each patient.
cNumber of complete reads obtained from each sample by UDPS.
dDiversity was calculated by the use of DNA distance (Phylip package), and is expressed as mean substitutions/site · 10)4.
eCalculated by Mann–Whitney U-test.
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disease (3/8 in group A vs. 0/19 in group B, p 0.04). As
expected, the efficiency of detection of multiple variants by
Ss was much lower, as polymorphisms were detected in only
two patients of group A (patients 2 and 5), where the intra-
patient prevalence of variants, estimated by UDPS, was >19%
(Table 1).
Besides the substitutions at codon 222, UDPS revealed
several substitutions at additional positions in the analysed
region, with respect to the reference strain (Table 2). S203T
was always observed as >98% of the quasi-species compo-
nents, consistent with the predominant clade 7 origin of Ital-
ian isolates [21]. Excluding S203T, a total of 27 non-D222
substitutions were detected, involving more frequently
group A than group B patients (8/8 vs. 6/19, respectively,
p 0.003). This was consistent with the increased heterogene-
ity in severe as compared with moderate–mild cases. All of
these substitutions, with the exception of V199A and R205K,
were present as minority variants (range of intrasample fre-
quency: 0.22–1.97%). A stop codon was detected at posi-
tion 188 in patient 11, as a minority variant (0.78%). Seven
of the non-D222 substitutions had not been previously
described (S203R, P218L, V220M, K239Q, G264S, T270A,
and T277I; Table 2).
Discussion
In this study, attention was paid to influenza A(H1N1)pdm09
HA quasi-species analysed by UDPS directly in clinical sam-
ples, with the aim of evaluating genetic heterogeneity and
quantifying D222 variants present in viral quasi-species within
each infected patient. Higher heterogeneity was observed in
the samples collected from severe patients than in those col-
lected from moderate–mild patients, and this difference was
not dependent on sample type or the duration of infection.
Concerning the position 222 variants, the concomitant
presence of multiple variants, including E/D, E/D/G, D/N/G
and D/N/G/E/A, was revealed by UDPS in >40% of patients.
These variants represented either predominant or minority
components of viral quasi-species, and were not revealed by
Ss when present at low frequency (i.e. <19%).
The presence of multiple D222 variants has been found in
clinical samples by studies based on either standard popula-
tion sequencing or a cloning/sequencing approach: Drews
et al. [22] observed the D/N/G polymorphism in a severe
patient, and Wang et al. [23] detected a mixture of D/N/G/S
in both ICU and mild patients. Mixed viruses with D222G/A
in patients with severe manifestations have also been
reported in one Spanish patient [10].
NGS, based on the shotgun approach, was used in a study
by Kuroda et al. [16], who reported D/N/G in a lung autopsy
sample from a patient who died of viral pneumonia with
influenza A(H1N1)pdm09 infection. In this study, variants
carrying D222G/N were detected as minority components
of viral quasi-species. More recently, Yasugi et al. [24]
reported the presence of minority variants at position 222 in
the HA from clinical samples obtained early during the influ-
enza A(H1N1)pdm09 pandemic.
The present study has addressed for the first time, with
an amplicon-based UDPS approach, the issue of genetic het-
erogeneity and polymorphisms at position 222 with respect
to the severity of clinical presentation. The reference D222
was detected by UDPS in all patients, as a minor, relevant or
even exclusive component of viral quasi-species. D222E
appeared to be the most frequent variant, in both severe
and moderate–mild patients, confirming the lack of associa-
tion with disease severity previously reported [2].
In our series, the D222G/N variants (eventually present as
minor components of viral quasi-species) were observed only
in patients with a severe clinical presentation, in keeping with
previous data [2,3,7,8].
Although no paired samples (NS and BAL) from severe
patients were available in this study, cross-sectional data from
previous studies indicate that these variants are more
TABLE 2. Frequency of non-D222 substitutions detected by
ultra-deep pyrosequencing in the patients with severe
(group A) and moderate–mild (group B) clinical presenta-
tions; the substitutions that have never been reported in
the literature are in bold










Q188stop – – – 1 0.78 11
D196G 1 0.84 4 – – –
V199A – – – 1 95.47 18
S203Ib 1 0.27 1 – – –
S203R – – – 2 0.33; 0.38 19; 17
R205G 1 0.33 1 – – –
R205K 2 94.36; 99.64 2; 6 1 99.53 16
P218L 1 0.31 2 – – –
V220M 1 0.22 5 – – –
R221K 1 0.58 8 – – –
E235K 1 0.29 1 – – –
E235G 2 0.39; 0.27 1; 5 – – –
K239Q 1 0.28 5 – – –
T241K 1 0.68 9 (NS)
V249M 1 0.27 3 – – –
M257I – – – 1 0.52 18
E258K 1 0.40 2 – – –
G264S 1 0.36 2 – – –
T270A 1 0.29 5 – – –
P271L – – – 1 0.35 19
V272A 1 0.29 5 – – –
V272I 1 1.97 7 – – –
N276D 1 0.38 5 – – –
T277I 1 0.31 1 – – –
NS, nasal swab.
an, number of patients showing the indicated substitution.
bThe frequency of S203T, present as a majority variant in all of the samples, has
been omitted.
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frequent in the lower than in the upper respiratory specimens
[3,9]. Several studies have indicated that D222G confers
enhanced binding to a2–3-linked sialic acids, suggesting a
greater ability to bind to the lung cells in the lower respiratory
tract and cause an exacerbation of disease [7,25]. Further-
more, Belser et al. [26] have mutated an influenza
A(H1N1)pdm09 virus to generate D222G, in order to study
the role of D222G in pathogenesis and transmission in ferret
and mouse models. Although the presence of this mutation
did not cause a significant increase in pathogenesis and trans-
mission in ferrets, it caused heightened virulence in mice, and
exhibited enhanced replication in human respiratory cells.
The possible clinical significance of minor components of
viral quasi-species is an attractive field of investigation, and
may unravel new aspects of viral pathogenesis. Concerning
influenza, enhanced cytopathogenicity for the lower respira-
tory tract, exerted by an even minute fraction of the repli-
cating viral population, may lead to strong functional
impairment of the respiratory epithelium, and to a more
severe clinical presentation. In addition, the interplay of
minority components of viral quasi-species with the cellular
immune response may cause early viral adaptation and
escape from immune control (as has been described to
occur in primary HIV infection [27]), possibly leading to
increased severity.
The presence of multiple variants in individual patients
(and, possibly, in different body compartments), showing very
diverse frequencies, seems not to be limited to position 222,
but to be a general phenomenon, and supports the hypothesis
of viral evolution within individual patients. The implications
of these findings are particularly interesting from a pathoge-
netic and epidemiological standpoint, as they suggest that the
emergence and the predominance of a more aggressive vari-
ant may be a single-patient-dependent phenomenon. Viral
diversity was not correlated with the time interval between
the start of symptoms and sample collection, so the increased
diversity in group A could not be accounted for only by
longer disease duration in this group (see Results). However,
more information on this point may come in the future from
the analysis of sequential samples from individual patients. In
addition, future studies should be focused on the identifica-
tion of factors that promote the evolution of influenza virus
strains in single individuals. In fact, in other respiratory viral
diseases (e.g. rhinovirus infections), the ability of the virus to
invade the lower respiratory tract and lead to protracted
infection is correlated with an impaired host immune
response, rather than with viral genetic characteristics [28].
One limitation of the present study is the small number of
analysed patients; despite this limitation, the results clearly
show that UDPS allows the detection of variants present
eventually as minute proportions of the overall quasi-species,
evaluation of their contribution to the viral quasi-species in
each single patient, and correlation of their presence with
clinical severity.
The short region analysed represents an important draw-
back of studies performed with UDPS; in fact, different viral
genome regions may differ substantially in the extent of vari-
ability, particularly for RNA viruses. In particular, HA repre-
sents one of the most variable influenza virus genome regions
in both intrapatient and interpatient analyses [13,21], with a
strong immune selection pressure, as indicated by the non-
synonymous/synonymous substitution ratio, which is higher
than in other genome segments [21]. Therefore, interpreta-
tion of the heterogeneity data obtained from UDPS analysis
of a short HA fragment requires caution, and the conclusions
cannot be simply extrapolated to the entire viral genome.
Despite this, we think that these result may represent a
proof of concept and a starting point for further studies on the
application of UDPS in the investigation of the role of (minor)
variants of influenza virus quasi-species in disease severity.
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